perflexane has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andres, KL; Kleinschmidt, SE; Krisko, RM; Longnecker, MP; Olsen, GW; Porter, AK; Reusch, CN; Taiwo, OA | 1 |
1 other study(ies) available for perflexane and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances.
Topics: Alkanesulfonic Acids; Antibodies, Neutralizing; Antibody Formation; Caprylates; COVID-19; COVID-19 Vaccines; Environmental Pollutants; Fluorocarbons; Follow-Up Studies; Humans; Immunoglobulin G; Sulfonic Acids | 2022 |